In addition, ICI therapy was found to be associated with increased risks of grade 1-5 hypothyroidism and hyperthyroidism compared with PTX+ICI, while PD-L1+PTX presented a lower risk of hypothyroidism compared to PD-L1. The gene discussed is CD274; the disease is hyperthyroidism.